Doctor of Podiatric Medicine Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jan Golden

Podiatrist, Foot & Ankle Surgery Scranton, PA Doctor of Podiatric Medicine

NPI 1003064726 CMS profile 1132083

3 W Olive St, Scranton, PA 18508

Open in the dashboard

General payments

$25,957

69 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jan Golden of Scranton, PA is reported in the CMS Open Payments database as having received $25,957 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,034 43
2024 General $2,432 5
2023 General $170 7
2022 General $232 13
2021 General $90 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jan Golden
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Jan Golden were reported at $23,034. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Jan Golden Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $0 $191 $62–$691 $114
2021 $90 $329 $104–$1,341 $132
2022 $232 $419 $125–$1,611 $149
2023 $170 $377 $128–$1,164 $160
2024 $2,432 $394 $134–$1,168 $164
2025 $23,034 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $25,072 42 payments
  2. Smith+Nephew, Inc. $500 20 payments
  3. Kerecis Limited $142 3 payments
  4. Heron Therapeutics, Inc. $125 1 payment
  5. Organogenesis Inc. $81 1 payment
  6. AbbVie, Inc. $36 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,303 20 payments
  2. Food and Beverage $2,376 39 payments
  3. Travel and Lodging $2,278 10 payments
Products named General payments · program years 2021–2025
  1. WaveWriter Alpha Prime 16 $23,945 33 payments
  2. General - Pain Management $995 8 payments
  3. COLLAGENASE SANTYL $233 15 payments
  4. OASIS MICRO $146 1 payment
  5. ZYNRELEF $125 1 payment
  6. Kerecis Omega3 Wound $90 1 payment
  7. Kerecis Omega3 Surgibind $90 1 payment
  8. Kerecis Omega3 GraftGuide $90 1 payment
  9. Kerecis Omega3 SurgiClose $90 1 payment
  10. Affinity $81 1 payment
  11. Other $419 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

240

Median for Podiatry: 160

Drug cost

$2,881

Median for Podiatry: $2,368

Branded share of claims

5.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 68 $1,001
Econazole Nitrate Generic 24 $802
Doxycycline Hyclate Generic 38 $364
Cephalexin Generic 34 $226
Triamcinolone Acetonide Generic 13 $183
Acetaminophen-Codeine Acetaminophen With Codeine Brand 13 $149
Prednisone Generic 39 $122
Meloxicam Generic 11 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$111,595

Of which drugs: $107

Medicare patients

547

Average age 78

Services billed

3,364

317 women, 230 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 40%
Ischemic heart disease 37%
Chronic kidney disease 28%
Atrial fibrillation 25%
Depression 25%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 860 $86

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record